CD30 is under clinical development by Wuhan Bio-Raid Biotechnology and currently in Phase I for T-Cell Lymphomas.

WGc-043, the world's first mRNA therapeutic vaccine targeting EBV-positive tumors to achieve IND approval in both China and ...

CD30 is under clinical development by Wuhan Bio-Raid Biotechnology and currently in Phase I for T-Cell Leukemia.

Pathologically, NK-cell lymphomas are divided into extranodal NK-/T-cell lymphoma, nasal type and aggressive NK-cell leukemia by the WHO classification. Clinically, NK-cell lymphomas can be ...

Other names Subtypes: intravascular large B-cell lymphoma; intravascular NK/T-cell lymphoma; intravascular NK-cell lymphoma; Intravasular T-cell lymphoma Santucci et al. first reported a case of IVL ...

Assisted Reproduction Unit, Department of Obstetrics and Gynecology, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, 310016, China Zhejiang Provincial Clinical Research ...

Chronic infection by Human T-lymphotropic virus type 1 (HTLV-1) and Epstein-Barr virus (EBV) causes an immune dysregulation that may culminate in malignant, inflammatory, and infectious disorders in ...

1 University of Rochester School of Medicine and Dentistry, Rochester, NY, United States 2 Department of Imaging Sciences, University of Rochester Medical Center, Rochester, NY, United States ...